CLINICAL_TRIALS
trial_result
· 2021-08-04
Clinical Trial Update: Evaluate Bioequivalence of Palonosetron (0.25mg/5mL) [Phase 4]
Summary
Phase 4 study evaluating bioequivalence of Palonosetron 0.25 mg per 5 mL for chemotherapy-induced nausea and vomiting prophylaxis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Yung Shin Pharm. Ind. Co., Ltd. | Conditions: Chemotherapy-induced Nausea and Vomiting, Prophylaxis | Phase 4 | Status: COMPLETED